WO2024146489A1 - 一种天然双层重组类胶原蛋白可吸收生物膜及其制备方法与应用 - Google Patents
一种天然双层重组类胶原蛋白可吸收生物膜及其制备方法与应用 Download PDFInfo
- Publication number
- WO2024146489A1 WO2024146489A1 PCT/CN2024/070015 CN2024070015W WO2024146489A1 WO 2024146489 A1 WO2024146489 A1 WO 2024146489A1 CN 2024070015 W CN2024070015 W CN 2024070015W WO 2024146489 A1 WO2024146489 A1 WO 2024146489A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- collagen
- minutes
- absorbable
- preparation
- layer
- Prior art date
Links
- 108010035532 Collagen Proteins 0.000 title claims abstract description 139
- 102000008186 Collagen Human genes 0.000 title claims abstract description 139
- 229920001436 collagen Polymers 0.000 title claims abstract description 139
- 238000002360 preparation method Methods 0.000 title claims abstract description 22
- 239000012528 membrane Substances 0.000 claims abstract description 47
- 238000000034 method Methods 0.000 claims abstract description 27
- 210000000988 bone and bone Anatomy 0.000 claims abstract description 26
- 238000004132 cross linking Methods 0.000 claims abstract description 24
- 230000007547 defect Effects 0.000 claims abstract description 20
- 238000004108 freeze drying Methods 0.000 claims abstract description 19
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 16
- 238000003825 pressing Methods 0.000 claims abstract description 4
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 24
- 230000008569 process Effects 0.000 claims description 21
- 238000001035 drying Methods 0.000 claims description 16
- 229910052757 nitrogen Inorganic materials 0.000 claims description 12
- 239000000463 material Substances 0.000 claims description 6
- 210000000963 osteoblast Anatomy 0.000 claims description 6
- 238000001356 surgical procedure Methods 0.000 claims description 5
- 239000004053 dental implant Substances 0.000 claims description 4
- 239000012567 medical material Substances 0.000 claims description 4
- 238000010438 heat treatment Methods 0.000 claims description 3
- 238000000859 sublimation Methods 0.000 claims description 2
- 230000008022 sublimation Effects 0.000 claims description 2
- 238000003795 desorption Methods 0.000 claims 2
- 230000002045 lasting effect Effects 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 10
- 230000008439 repair process Effects 0.000 abstract description 9
- 230000004069 differentiation Effects 0.000 abstract description 3
- 230000012010 growth Effects 0.000 abstract description 3
- 230000001939 inductive effect Effects 0.000 abstract description 3
- 210000004379 membrane Anatomy 0.000 description 42
- 238000007710 freezing Methods 0.000 description 24
- 230000008014 freezing Effects 0.000 description 24
- 239000008176 lyophilized powder Substances 0.000 description 14
- 239000008213 purified water Substances 0.000 description 13
- 238000009777 vacuum freeze-drying Methods 0.000 description 13
- 125000000539 amino acid group Chemical group 0.000 description 8
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 8
- 238000001000 micrograph Methods 0.000 description 8
- 239000001301 oxygen Substances 0.000 description 8
- 229910052760 oxygen Inorganic materials 0.000 description 8
- 210000004027 cell Anatomy 0.000 description 6
- 238000010586 diagram Methods 0.000 description 6
- 239000007943 implant Substances 0.000 description 6
- 108090000623 proteins and genes Proteins 0.000 description 6
- 102000004169 proteins and genes Human genes 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- 241000235058 Komagataella pastoris Species 0.000 description 3
- 230000015556 catabolic process Effects 0.000 description 3
- 230000000052 comparative effect Effects 0.000 description 3
- 238000006731 degradation reaction Methods 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 210000000887 face Anatomy 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 241000700159 Rattus Species 0.000 description 2
- 101710137510 Saimiri transformation-associated protein Proteins 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 210000004204 blood vessel Anatomy 0.000 description 2
- 230000010478 bone regeneration Effects 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 238000006073 displacement reaction Methods 0.000 description 2
- 238000000855 fermentation Methods 0.000 description 2
- 230000004151 fermentation Effects 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 238000002513 implantation Methods 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 238000011835 investigation Methods 0.000 description 2
- 230000014759 maintenance of location Effects 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 239000002994 raw material Substances 0.000 description 2
- 238000010186 staining Methods 0.000 description 2
- BRZYSWJRSDMWLG-DJWUNRQOSA-N (2r,3r,4r,5r)-2-[(1s,2s,3r,4s,6r)-4,6-diamino-3-[(2s,3r,4r,5s,6r)-3-amino-4,5-dihydroxy-6-[(1r)-1-hydroxyethyl]oxan-2-yl]oxy-2-hydroxycyclohexyl]oxy-5-methyl-4-(methylamino)oxane-3,5-diol Chemical compound O1C[C@@](O)(C)[C@H](NC)[C@@H](O)[C@H]1O[C@@H]1[C@@H](O)[C@H](O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H]([C@@H](C)O)O2)N)[C@@H](N)C[C@H]1N BRZYSWJRSDMWLG-DJWUNRQOSA-N 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 108010009565 Bio-Gide Proteins 0.000 description 1
- 229920001661 Chitosan Polymers 0.000 description 1
- 102000012422 Collagen Type I Human genes 0.000 description 1
- 108010022452 Collagen Type I Proteins 0.000 description 1
- 208000037408 Device failure Diseases 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- 101001121408 Homo sapiens L-amino-acid oxidase Proteins 0.000 description 1
- 101000827703 Homo sapiens Polyphosphoinositide phosphatase Proteins 0.000 description 1
- 206010021143 Hypoxia Diseases 0.000 description 1
- 102100026388 L-amino-acid oxidase Human genes 0.000 description 1
- 208000015371 Mandibular injury Diseases 0.000 description 1
- SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 102100023591 Polyphosphoinositide phosphatase Human genes 0.000 description 1
- 101100012902 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) FIG2 gene Proteins 0.000 description 1
- 101100233916 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) KAR5 gene Proteins 0.000 description 1
- 206010062255 Soft tissue infection Diseases 0.000 description 1
- 206010052428 Wound Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 238000007605 air drying Methods 0.000 description 1
- 125000003275 alpha amino acid group Chemical group 0.000 description 1
- 230000003872 anastomosis Effects 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 239000000560 biocompatible material Substances 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 230000036770 blood supply Effects 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 229920001577 copolymer Polymers 0.000 description 1
- 230000000994 depressogenic effect Effects 0.000 description 1
- 238000004520 electroporation Methods 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 239000013604 expression vector Substances 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 230000001146 hypoxic effect Effects 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 238000004255 ion exchange chromatography Methods 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 230000006996 mental state Effects 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 210000000214 mouth Anatomy 0.000 description 1
- 210000002200 mouth mucosa Anatomy 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 230000011164 ossification Effects 0.000 description 1
- 229920000747 poly(lactic acid) Polymers 0.000 description 1
- 229920005597 polymer membrane Polymers 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 210000004872 soft tissue Anatomy 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000017423 tissue regeneration Effects 0.000 description 1
- 230000000472 traumatic effect Effects 0.000 description 1
- YFHICDDUDORKJB-UHFFFAOYSA-N trimethylene carbonate Chemical compound O=C1OCCCO1 YFHICDDUDORKJB-UHFFFAOYSA-N 0.000 description 1
- 238000000108 ultra-filtration Methods 0.000 description 1
- 238000001291 vacuum drying Methods 0.000 description 1
- 230000029663 wound healing Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
- A61L27/58—Materials at least partially resorbable by the body
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/14—Macromolecular materials
- A61L27/22—Polypeptides or derivatives thereof, e.g. degradation products
- A61L27/24—Collagen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
- A61L31/04—Macromolecular materials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2430/00—Materials or treatment for tissue regeneration
- A61L2430/02—Materials or treatment for tissue regeneration for reconstruction of bones; weight-bearing implants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2430/00—Materials or treatment for tissue regeneration
- A61L2430/12—Materials or treatment for tissue regeneration for dental implants or prostheses
Definitions
- the natural double-layer recombinant collagen absorbable biomembrane is a biocompatible material that uses surgery to place the membrane between the oral soft tissue and the bone defect to establish a biological barrier, thereby creating a relatively closed bone regeneration environment, selectively blocking the faster migrating fibroblasts and epithelial cells from entering the bone defect area, while not hindering the natural healing of the wound.
- the natural double-layer recombinant collagen absorbable biomembrane can be divided into collagen membrane, polymer membrane, tissue membrane, chitosan membrane and other types of membranes.
- the collagen is the recombinant human collagen disclosed in CN106554410A, and the recombinant human collagen comprises one or more of the following family members:
- Prefreezing It is carried out in two stages.
- the process parameters of the first stage of prefreezing are that the temperature reaches 0-4°C within 10-60 minutes and lasts for 30-120 minutes;
- the process parameters of the second stage of prefreezing are that the temperature reaches -60°C to -40°C within 10-60 minutes and lasts for 120-480 minutes;
- the thickness of the film is 0.1-1 mm, for example, 0.1 mm, 0.2 mm, 0.3 mm, 0.4 mm, 0.5 mm, 0.6 mm, 0.7 mm, 0.8 mm, 0.9 mm or 1 mm, etc.
- the dry heat crosslinking is: placing the film in an environment with a vacuum degree of -0.1 to -0.05 MPa or nitrogen, heating it to 100-250°C and maintaining it for 1-6 hours.
- the heating temperature is 100-230°C.
- one side of the natural double-layer recombinant collagen-like absorbable biomembrane is a dense structure, and the other side is a loose structure.
- the present invention also provides the use of the natural double-layer recombinant collagen-like absorbable biofilm in the preparation of oral medical materials.
- the oral medical material is a material used for oral restoration or oral surgery.
- the oral restoration comprises dental implantation.
- the dense layer faces outward to block non-osteoblasts outside the bone defect area, and the loose layer faces inward toward the bone defect site to allow osteoblasts to enter the bone defect area smoothly.
- the present invention uses the recombinant collagen of Shaanxi Huikang Biotechnology Co., Ltd. (patent number: ZL201610388271.8, a recombinant human collagen and its encoding gene and preparation method) as raw material, and uses dry heat cross-linking under low oxygen content or relatively anaerobic conditions to obtain a natural double-layer recombinant collagen absorbable biofilm composed of a loose layer and a dense layer (i.e., a loose structure on one side and a dense structure on the other side).
- the loose layer faces inward toward the bone defect site, allowing osteoblasts to smoothly enter the bone defect area, and the natural double-layer recombinant collagen absorbable biofilm can promote the proliferation of capillaries, allowing capillaries to grow into the bone defect area, prompting the new blood vessels to further anastomose with the blood vessels around the bone defect area, and finally forming a complete blood supply system in the bone defect area;
- the natural double-layer recombinant collagen absorbable biofilm of the present invention can be degraded in the body, has a low immune rejection reaction, has the effects of accelerating growth and actively inducing differentiation, can promote the repair of bone defect areas, can be widely used in oral medicine fields such as periodontology, oral implants and alveolar surgery, and the membrane can stabilize bone grafting particles, avoid displacement of bone grafting particles, improve bone formation quality, and greatly improve the survival rate of implants.
- FIG1 is a scanning electron microscope image of a collagen membrane
- FIG4 is a scanning electron microscope image of a cross section of a biofilm
- Figure 5 is a diagram showing the appearance of a biofilm
- FIG6 is an appearance diagram of the membrane obtained by dry heat crosslinking treatment under aerobic, hypoxic and nitrogen conditions
- Figure 7 is a biofilm toughness test diagram
- FIG8 is a graph showing a biofilm viscosity test
- FIG9 is a staining diagram of a biofilm applied subcutaneously to a section of a SD rat;
- FIG10 is a diagram showing the results of the biofilm cell compatibility study
- FIG. 11 is a diagram showing the results of biofilm promoting vascularization.
- the recombinant collagen-like lyophilized powder used in the following examples is designed by optimizing the amino acid sequence, and a novel recombinant collagen-like protein is highly expressed by Pichia pastoris (see patent application publication text CN106554410A), and is obtained through large-scale fermentation and purification.
- the hydrophilic Gly-X-Y repeating sequence is the minimum repeating unit of human type I collagen
- the novel collagen nucleotide sequence is designed by targeted arrangement and combination
- the expression vector pPIC9K of Pichia pastoris is expressed in the Pichia pastoris host bacterium GS115 by electroporation.
- the expression of the high-copy strain is expanded through the fermentation process, and the high-purity recombinant collagen-like protein is obtained by ultrafiltration and ion exchange chromatography purification.
- recombinant collagen lyophilized powder (recombinant human collagen obtained in Example 1 of patent application publication CN106554410A), add purified water to 30 g, suspend evenly, and prepare 30 ml of 3% collagen solution; add into a 1.6 ⁇ 1.6 cm mold and perform vacuum freeze drying to obtain 36 collagen membranes; press the collagen membrane to a thickness of 0.5 mm; perform dry heat crosslinking in a nitrogen-filled vacuum oven at 100° C. for 6 h to obtain the natural double-layer recombinant collagen absorbable biofilm;
- the temperature In the first stage of pre-freezing, the temperature reaches 0°C within 50 minutes and lasts for 60 minutes; in the second stage of pre-freezing, the temperature reaches -45°C within 50 minutes and lasts for 240 minutes;
- the scanning electron microscope image of the natural double-layer recombinant collagen-like absorbable biofilm is shown in Figure 1, which shows the collagen membrane with a three-dimensional structure after freeze-drying; the scanning electron microscope image of the loose surface of the biofilm is shown in Figure 2; the scanning electron microscope image of the dense surface of the biofilm is shown in Figure 3; the scanning electron microscope image of the cross-section of the biofilm is shown in Figure 4, and the appearance of the biofilm is shown in Figure 5.
- the temperature In the first stage of pre-freezing, the temperature reaches 1°C within 40 minutes and lasts for 50 minutes; in the second stage of pre-freezing, the temperature reaches -40°C within 50 minutes and lasts for 300 minutes;
- This embodiment provides a natural double-layer recombinant collagen-like absorbable biomembrane, which is prepared by the following steps:
- This embodiment provides a natural double-layer recombinant collagen-like absorbable biomembrane, which is prepared by the following steps:
- recombinant collagen lyophilized powder (recombinant human collagen obtained in Example 1 of patent application publication CN106554410A), add purified water to 30g, suspend evenly, prepare 30ml 5% collagen solution, add into a 1.6 ⁇ 1.6cm mold and perform vacuum freeze drying to obtain 36 collagen films; press the collagen film to a thickness of 0.7mm; perform dry heat crosslinking at 200°C in a low-pressure vacuum oven (low oxygen conditions) for 2.5h to obtain the natural double-layer recombinant collagen absorbable biofilm;
- freeze drying process is:
- Example 9-Example 14 respectively provide a natural double-layer recombinant collagen absorbable biomembrane, and the preparation method is the same as that of Example 1, except that the concentration of the collagen solution is different, which is 1%, 2%, 4%, 5%, 6%, and 7% respectively.
- freeze drying process is:
- the temperature In the first stage of pre-freezing, the temperature reaches 2°C within 30 minutes and lasts for 60 minutes; in the second stage of pre-freezing, the temperature reaches -50°C within 60 minutes and lasts for 240 minutes;
- This comparative example provides a natural double-layer recombinant collagen-like absorbable biomembrane, which is prepared by the following steps:
- recombinant collagen lyophilized powder (recombinant human collagen obtained in Example 1 of patent application publication CN106554410A), add purified water to 30g, suspend evenly, prepare 30ml 7% collagen solution, add into a 1.6 ⁇ 1.6cm mold and perform vacuum freeze drying to obtain 36 collagen films; press the collagen film to a thickness of 0.5mm; perform dry heat crosslinking in a forced air drying oven at 240°C for 1.5h to obtain the natural double-layer recombinant collagen absorbable biofilm;
- freeze drying process is:
- the biofilm obtained in Example 1 has good toughness, as shown in FIG. 7 ; and good viscosity, as shown in FIG. 8 ; the mechanical property test results of the biofilms with different collagen concentrations are shown in Tables 2 to 4.
- the biofilm obtained in Example 1 was embedded subcutaneously in SD rats, and the samples were longitudinally cut and HE stained in the third week.
- the section staining was shown in Figure 9, and it can be seen that the biofilm has a large number of cell infiltrations and has good biocompatibility; the cell compatibility investigation results of the biofilm obtained in Example 8 are shown in Figure 10, and the cells continued to proliferate in the first three days, indicating that the membrane has good cell compatibility.
- the 6% collagen membrane extract in Figure 10 refers to the collagen membrane (the concentration of the collagen solution in the preparation process is 6%) placed in the culture medium (H-DMEM+10% FBS) for 24h, and the extract was used to inoculate cells in a 96-well plate; the 6% collagen raw material is the recombinant collagen lyophilized powder used in Example 8 plus purified water to prepare a 6% collagen solution.
- the results of promoting vascularization of the biofilm obtained in Example 1 are shown in Figure 11, and it can be seen that nutrients can smoothly penetrate the membrane, which is beneficial to wound healing, promotes early vascularization, and guides bone tissue regeneration.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Oral & Maxillofacial Surgery (AREA)
- Transplantation (AREA)
- Medicinal Chemistry (AREA)
- Dermatology (AREA)
- Chemical & Material Sciences (AREA)
- Biophysics (AREA)
- Heart & Thoracic Surgery (AREA)
- Surgery (AREA)
- Vascular Medicine (AREA)
- Materials For Medical Uses (AREA)
Abstract
一种天然双层重组类胶原蛋白可吸收生物膜及其制备方法与应用;该制备方法包括以下步骤:(1)将胶原蛋白溶解到水中得到胶原蛋白溶液;(2)对上述胶原蛋白溶液进行冷冻干燥,得到胶原膜;(3)将上述胶原膜压制成薄膜;(4)对上述薄膜进行干热交联,得到所述天然双层重组类胶原蛋白可吸收生物膜。由该方法制得的生物膜具备疏松层和致密层,生物相容性、机械性能和韧性良好,具有加速生长和主动诱导分化的作用,可促进骨缺损区的修复等特点。
Description
本发明涉及医疗器械技术领域,尤其涉及一种天然双层重组类胶原蛋白可吸收生物膜及其制备方法与应用。
口腔种植修复技术是口腔医学发展的重要革命,因其具有良好的固位、逼真的美观效果,极大提高了种植牙患者的生活质量和精神状态。种植牙的长期成功率依赖多种因素,其中包括种植位点的选择、软硬组织形态的状态和种植体周边骨质是否完好、骨粉种植量等等。牙种植技术成为目前牙缺失修复的常用手段,临床上由于缺牙后部性骨吸收以及外伤性缺牙时的骨组织缺损,常有一些过低、过窄或局部有凹陷的病例,40%-80%的患者存在骨量不足,在种植过程中常发生侧方穿孔,导致种植失败。
随着引导性骨再生技术在临床上的应用,上述问题将得以解决。天然双层重组类胶原蛋白可吸收生物膜是利用外科手术的方式将膜置于口腔软组织与骨缺损之间建立生物屏障,以此创造一个相对封闭的骨再生环境,选择性地阻挡迁移速度较快的成纤维细胞和上皮细胞进入骨缺损区,而同时又不妨碍伤口自然愈合的一种生物相容性材料。目前天然双层重组类胶原蛋白可吸收生物膜可分为胶原膜、高分子聚合膜、组织膜、壳聚糖膜和其它种类膜。但这些类型的膜或多或少都存在一定的缺陷,例如降解速度慢、或价格昂贵、或材料过硬不利用临床使用等。单一类型材料组成的膜不能完全达到膜修复引导的效果,因此多种材料的复合共混来达到更优的治疗效果是近几年研究的热点。Pan SX等将左旋聚丙交酯、N-甲基吡咯烷酮与三亚甲基碳酸酯及其共聚物复合成膜,修复羊的下颔骨损伤,该材料可促进膜的降解,避免二次手术,降低了患者疼痛及经济负担。目前进口胶原膜中Bio-Gide生物膜效果稳定但是价格较高。福建博远公司生产的博特医用胶原膜由于其工艺简单价格便宜,在临床上得到了广泛的应用,但是对温度要求高,需要在2-5℃的低温条件下保存。烟台正海生物公司生产的海奥口腔修复膜应用于口腔黏膜的修复,由于其植入口腔后四周易翘起,增加了其使用后的风险。天然双层重组类胶原蛋白可吸收生物膜的出现极大地推动了口腔修复医学的发展,它不仅解决了口腔修复中的骨缺损问题,而且还满足了口腔美学的要求。但天然双层重组类胶原蛋白可吸收生物膜在临床使用中仍存在膜暴露及感染、膜塌陷及移位、软组织感染、抗原性、不可吸收膜的体内置留时间、可吸收膜的体内维持时间等问题,故研究一种安全有效,同时价格更为低廉的天然双层重组类胶原蛋白可吸收生物膜迫在眉睫。
发明内容
为了解决上述问题,本发明的目的在于提供一种天然双层重组类胶原蛋白可吸收生物膜及其制备方法与应用,由该方法制得的生物膜具备疏松层和致密层,生物相容性、机械性能和韧性良好,具有加速生长和主动诱导分化的作用,可促进骨缺损区的修复等特点。
为了达到上述目的,本发明提供了一种天然双层重组类胶原蛋白可吸收生物膜的制备方法,其包括以下步骤:
(1)将胶原蛋白溶解到水中得到胶原蛋白溶液;
(2)对上述胶原蛋白溶液进行冷冻干燥,得到胶原膜;
(3)将上述胶原膜压制成薄膜;
(4)对上述薄膜进行干热交联,得到所述天然双层重组类胶原蛋白可吸收生物膜。
根据本发明的具体实施方案,优选地,步骤(1)中,所述胶原蛋白为CN106554410A所公开的重组人源胶原蛋白,该重组人源胶原蛋白包含下列家族成员中的一种或几种:
1)具有序列表中SEQ ID No:1氨基酸残基序列的蛋白质;
2)与SEQ ID No:1氨基酸残基序列同源性在90%以上且具有与SEQ ID No:1相同活性的SEQ ID No:1衍生的蛋白质;
3)在SEQ ID No:1氨基酸残基序列的N-端增加或删除15个以内氨基酸残基得到的具有与SEQ ID No:1相同活性的SEQ ID No:1衍生的蛋白质;
4)在SEQ ID No:1氨基酸残基序列的C-端增加或删除15个以内氨基酸残基得到的具有与SEQ ID No:1相同活性的SEQ ID No:1衍生的蛋白质;
5)将SEQ ID No:1氨基酸残基序列经过一个或几个氨基酸残基的取代、缺失或添加且具有与SEQ ID No:1相同活性的SEQ ID No:1衍生的蛋白质。
根据本发明的具体实施方案,优选地,步骤(1)中,所述胶原蛋白溶液中胶原蛋白的质量浓度为0.5-15%,更优选为1-10%,例如1-7%。
根据本发明的具体实施方案,优选地,步骤(2)中,所述冷冻干燥的工艺包括以下步骤:
(1)预冻:分两个阶段进行,预冻第一阶段的工艺参数为在10-60min内,温度达0-4℃,并持续30-120min;预冻第二阶段的工艺参数为在10-60min内,温度达-60℃至-40℃,并持续120-480min;
(2)升华:对经预冻后的产物进行升华,真空度设为0.05-0.5mbar,在10-60min
内,温度达-40℃至-5℃,并持续120-480min;
(3)解析干燥:对经升华后的产物进行解析干燥,真空度设为0.05-0.5mbar,在10-60min内,温度达0-40℃,并持续120-480min;
工艺参数如下:
根据本发明的具体实施方案,优选地,步骤(3)中,所述压制包括将多层胶原膜叠加压制成一定厚度的薄膜。
根据本发明的具体实施方案,优选地,步骤(3)中,所述薄膜的厚度为0.1-1mm,例如0.1mm、0.2mm、0.3mm、0.4mm、0.5mm、0.6mm、0.7mm、0.8mm、0.9mm或1mm等。
根据本发明的具体实施方案,优选地,步骤(4)中,所述干热交联为:将所述薄膜置于真空度为-0.1至-0.05MPa或氮气的环境中升温至100-250℃后保持1-6h。
根据本发明的具体实施方案,优选地,在干热交联中,所述升温的温度为100-230℃。
根据本发明的具体实施方案,优选地,所述干热交联采用电热真空干燥箱或精密真空充氮一体烘箱进行。
根据本发明的具体实施方案,上述制备方法具体包括以下步骤:
配制胶原蛋白溶液,在配制溶液的过程中均匀搅拌溶液并静置;将该溶液加入冻干模具并进行真空冷冻干燥,得到具有三维结构的胶原膜;将胶原膜压制成薄膜;将薄膜在氧含量较低或相对无氧的条件下进行干热交联;灭菌,即得到所述天然双层重组类胶原蛋白可吸收生物膜。
本发明还提供了一种天然双层重组类胶原蛋白可吸收生物膜,其由上述制备方法制得。
根据本发明的具体实施方案,优选地,所述天然双层重组类胶原蛋白可吸收生物膜的一侧为致密结构,另一侧为疏松结构。
本发明还提供了上述天然双层重组类胶原蛋白可吸收生物膜在制备口腔医用材料中的应用。
根据本发明的具体实施方案,优选地,所述口腔医用材料为用于口腔修复或口腔外科手术的材料。
根据本发明的具体实施方案,优选地,所述口腔修复包括牙齿种植。
根据本发明的具体实施方案,优选地,所述天然双层重组类胶原蛋白可吸收生物膜在应用时,致密层朝外将非成骨细胞阻挡于骨缺损区以外,疏松层向内朝向骨缺损部位使成骨细胞顺利进入骨缺损区。
本发明以陕西慧康生物科技有限责任公司的重组类胶原蛋白(专利号:ZL201610388271.8,一种重组人源胶原蛋白及其编码基因和制备方法)为原料,利用在氧含量较低或相对无氧的条件下进行干热交联,得到由疏松层和致密层组成的(即一侧为疏松结构,另一侧为致密结构)天然双层重组类胶原蛋白可吸收生物膜,该生物膜具有良好的生物相容性、机械性能和韧性,无毒、无抗原反应,免疫原性低,降解可控;且具有一定的粘性,可有效贴附于使用部位,隔离效果好,其致密层朝外能够选择性地将非成骨细胞阻挡于骨缺损区以外,疏松层向内朝向骨缺损部位使成骨细胞顺利进入骨缺损区,并且所述的天然双层重组类胶原蛋白可吸收生物膜可促进毛细血管的增生,使得毛细血管向骨缺损区长入,促使新生血管与骨缺损区周围血管进一步吻合,最终在骨缺损区形成完整的供血系统;本发明的天然双层重组类胶原蛋白可吸收生物膜其可在体内降解,免疫排斥反应低,具有加速生长和主动诱导分化的作用,可促进骨缺损区的修复,可广泛应用于牙周科、口腔种植及牙槽外科等口腔医学领域,并且该膜可以稳定植骨颗粒,避免植骨颗粒的移位,提高成骨质量,大大提高种植体的生存率。
图1为胶原膜的扫描电子显微镜图;
图2为生物膜疏松面的扫描电子显微镜图;
图3为生物膜致密面的扫描电子显微镜图;
图4为生物膜的截面的扫描电子显微镜图;
图5为生物膜外观图;
图6为分别在有氧、低氧、充氮气条件下经干热交联处理所得膜的外观图;
图7为生物膜韧性测试图;
图8为生物膜粘性测试图;
图9为生物膜应用于SD大鼠皮下后的切片染色图;
图10为生物膜细胞相容性考察结果图;
图11为生物膜促进血管化结果图。
为了对本发明的技术特征、目的和有益效果有更加清楚的理解,现对本发明的技术方案进行以下详细说明,但不能理解为对本发明的可实施范围的限定。
需要说明的是,在说明书及权利要求当中使用了某些词汇来指称特定组件。本领域技术人员应可以理解,技术人员可能会用不同名词来称呼同一个组件。本说明书及权利要求并不以名词的差异作为区分组件的方式,而是以组件在功能上的差异作为区分的准则。如在通篇说明书及权利要求当中所提及的“包含”或“包括”为开放式用语,故应解释成“包含但不限定于”。说明书后续描述为实施本发明的较佳实施方式,然而所述描述乃以说明书的一般原则为目的,并非用以限定本发明的范围。本发明的保护范围当视所附权利要求所界定者为准。
以下实施例采用的重组类胶原蛋白冻干粉是通过优化的氨基酸序列设计,通过毕赤酵母高表达新型重组类胶原蛋白(参见专利申请公布文本CN106554410A),经过大规模发酵和纯化所得,具体为:亲水性Gly-X-Y重复序列是人I.型胶原蛋白的最小重复单位,靶向排列和组合以设计新型胶原核苷酸序列,然后通过电转化在毕赤酵母宿主细菌GS115中表达毕赤酵母的表达载体pPIC9K,在抗生素G418筛选后通过发酵过程扩大高拷贝菌株的表达,经超滤和离子交换色谱纯化得到高纯度重组类胶原蛋白。
实施例1
本实施例提供了一种天然双层重组类胶原蛋白可吸收生物膜,其由以下步骤制得:
称量0.9g重组类胶原蛋白冻干粉(专利申请公布文本CN106554410A中实施例1所得重组人源胶原蛋白),加纯化水至30g,混悬均匀,配制得到30ml 3%的胶原蛋白溶液;加入1.6×1.6cm模具后进行真空冷冻干燥,制得36片胶原膜;将胶原膜压片至厚度为0.5mm;在充氮真空烘箱于100℃进行干热交联6h即得所述天然双层重组类胶原蛋白可吸收生物膜;
其中,冷冻干燥工艺为:
(1)预冻第一阶段,在50min内,温度达0℃,并持续60min;预冻第二阶段,在50min内,温度达-45℃,并持续240min;
(2)对经预冻后的产物进行升华,真空度设为0.05mbar,在60min内,温度达-10℃,并持续300min;
(3)对经升华后的产物进行解析干燥,真空度设为0.1mbar,在40min内,温度达
25℃,并持续240min。
该天然双层重组类胶原蛋白可吸收生物膜的扫描电子显微镜图如图1所示,其显示了冻干后具有三维结构的胶原膜;生物膜疏松面的扫描电子显微镜图如图2所示;生物膜致密面的扫描电子显微镜图如图3所示;生物膜的截面的扫描电子显微镜图如图4所示,该生物膜外观如图5所示。
实施例2
本实施例提供了一种天然双层重组类胶原蛋白可吸收生物膜,其由以下步骤制得:
称量1.8g重组类胶原蛋白冻干粉(专利申请公布文本CN106554410A中实施例1所得重组人源胶原蛋白),加纯化水至30g,混悬均匀,配制得到30ml 6%的胶原蛋白溶液;加入1.6×1.6cm模具后进行真空冷冻干燥,制得36片胶原膜;将胶原膜压片至厚度为0.6mm;在无氧烘箱(低氧条件)于140℃进行干热交联5h即得所述天然双层重组类胶原蛋白可吸收生物膜;
其中,冷冻干燥工艺为:
(1)预冻第一阶段,在40min内,温度达1℃,并持续50min;预冻第二阶段,在50min内,温度达-40℃,并持续300min;
(2)对经预冻后的产物进行升华,真空度设为0.08mbar,在50min内,温度达-20℃,并持续320min;
(3)对经升华后的产物进行解析干燥,真空度设为0.09mbar,在50min内,温度达30℃,并持续180min。
实施例3
本实施例提供了一种天然双层重组类胶原蛋白可吸收生物膜,其由以下步骤制得:
称量2.1g重组类胶原蛋白冻干粉(专利申请公布文本CN106554410A中实施例1所得重组人源胶原蛋白),加纯化水至30g,混悬均匀,配制得到30ml 7%的胶原蛋白溶液,加入1.6×1.6cm模具后进行真空冷冻干燥,制得36片胶原膜;将胶原膜压片至厚度为0.8mm;在低压真空烘箱(低氧条件)于220℃进行干热交联2h即得所述天然双层重组类胶原蛋白可吸收生物膜;
其中,冷冻干燥工艺为:
(1)预冻第一阶段,在30min内,温度达2℃,并持续60min;预冻第二阶段,在60min内,温度达-50℃,并持续240min;
(2)对经预冻后的产物进行升华,真空度设为0.07mbar,在60min内,温度达-5℃,
并持续350min;
(3)对经升华后的产物进行解析干燥,真空度设为0.1mbar,在40min内,温度达35℃,并持续150min。
实施例4
本实施例提供了一种天然双层重组类胶原蛋白可吸收生物膜,其由以下步骤制得:
称量0.3g重组类胶原蛋白冻干粉(专利申请公布文本CN106554410A中实施例1所得重组人源胶原蛋白),加纯化水至30g,混悬均匀,配制得到30ml 1%的胶原蛋白溶液;加入1.6×1.6cm模具后进行真空冷冻干燥,制得36片胶原膜;将胶原膜压片至厚度为0.5mm;在充氮真空烘箱于100℃进行干热交联6h即得所述天然双层重组类胶原蛋白可吸收生物膜;
其中,冷冻干燥工艺为:
(1)预冻第一阶段,在50min内,温度达0℃,并持续60min;预冻第二阶段,在50min内,温度达-45℃,并持续240min;
(2)对经预冻后的产物进行升华,真空度设为0.05mbar,在60min内,温度达-10℃,并持续300min;
(3)对经升华后的产物进行解析干燥,真空度设为0.1mbar,在40min内,温度达25℃,并持续240min。
实施例5
本实施例提供了一种天然双层重组类胶原蛋白可吸收生物膜,其由以下步骤制得:
称量0.6g重组类胶原蛋白冻干粉(专利申请公布文本CN106554410A中实施例1所得重组人源胶原蛋白),加纯化水至30g,混悬均匀,配制得到30ml 2%的胶原蛋白溶液;加入1.6×1.6cm模具后进行真空冷冻干燥,制得36片胶原膜;将胶原膜压片至厚度为0.6mm;在无氧烘箱(低氧条件)于150℃进行干热交联5h即得所述天然双层重组类胶原蛋白可吸收生物膜;
其中,冷冻干燥工艺为:
(1)预冻第一阶段,在40min内,温度达1℃,并持续50min;预冻第二阶段,在50min内,温度达-40℃,并持续300min;
(2)对经预冻后的产物进行升华,真空度设为0.08mbar,在50min内,温度达-20℃,并持续320min;
(3)对经升华后的产物进行解析干燥,真空度设为0.09mbar,在50min内,温度
达30℃,并持续180min。
实施例6
本实施例提供了一种天然双层重组类胶原蛋白可吸收生物膜,其由以下步骤制得:
称量1.2g重组类胶原蛋白冻干粉(专利申请公布文本CN106554410A中实施例1所得重组人源胶原蛋白),加纯化水至30g,混悬均匀,配制得到30ml 4%的胶原蛋白溶液,加入1.6×1.6cm模具后进行真空冷冻干燥,制得36片胶原膜;将胶原膜压片至厚度为0.6mm;在低压真空烘箱(低氧条件)于230℃进行干热交联2h即得所述天然双层重组类胶原蛋白可吸收生物膜;
其中,冷冻干燥工艺为:
(1)预冻第一阶段,在30min内,温度达2℃,并持续60min;预冻第二阶段,在60min内,温度达-50℃,并持续240min;
(2)对经预冻后的产物进行升华,真空度设为0.07mbar,在60min内,温度达-5℃,并持续350min;
(3)对经升华后的产物进行解析干燥,真空度设为0.1mbar,在40min内,温度达35℃,并持续150min。
实施例7
本实施例提供了一种天然双层重组类胶原蛋白可吸收生物膜,其由以下步骤制得:
称量1.5g重组类胶原蛋白冻干粉(专利申请公布文本CN106554410A中实施例1所得重组人源胶原蛋白),加纯化水至30g,混悬均匀,配制得到30ml 5%的胶原蛋白溶液,加入1.6×1.6cm模具后进行真空冷冻干燥,制得36片胶原膜;将胶原膜压片至厚度为0.7mm;在低压真空烘箱(低氧条件)于200℃进行干热交联2.5h即得所述天然双层重组类胶原蛋白可吸收生物膜;
其中,冷冻干燥工艺为:
(1)预冻第一阶段,在30min内,温度达2℃,并持续60min;预冻第二阶段,在60min内,温度达-50℃,并持续240min;
(2)对经预冻后的产物进行升华,真空度设为0.07mbar,在60min内,温度达-5℃,并持续350min;
(3)对经升华后的产物进行解析干燥,真空度设为0.2mbar,在40min内,温度达35℃,并持续150min。
实施例8
本实施例提供了一种天然双层重组类胶原蛋白可吸收生物膜,其由以下步骤制得:
称量1.8g重组类胶原蛋白冻干粉(专利申请公布文本CN106554410A中实施例1所得重组人源胶原蛋白),加纯化水至30g,混悬均匀,配制得到30ml 6%的胶原蛋白溶液;加入1.6×1.6cm模具后进行真空冷冻干燥,制得36片胶原膜;将胶原膜压片至厚度为0.5mm;在充氮真空烘箱于110℃进行干热交联5.5h即得所述天然双层重组类胶原蛋白可吸收生物膜;
其中,冷冻干燥工艺为:
(1)预冻第一阶段,在50min内,温度达4℃,并持续60min;预冻第二阶段,在50min内,温度达-45℃,并持续240min;
(2)对经预冻后的产物进行升华,真空度设为0.06mbar,在60min内,温度达-10℃,并持续300min;
(3)对经升华后的产物进行解析干燥,真空度设为0.18mbar,在40min内,温度达25℃,并持续240min。
实施例9-实施例14
实施例9-实施例14分别提供了一种天然双层重组类胶原蛋白可吸收生物膜,制备方法与实施例1相同,区别在于胶原蛋白溶液的浓度不同,分别为1%、2%、4%、5%、6%、7%。
实施例15
本实施例提供了一种天然双层重组类胶原蛋白可吸收生物膜,其由以下步骤制得:
称量0.9g重组类胶原蛋白冻干粉(专利申请公布文本CN106554410A中实施例3所得重组人源胶原蛋白),加纯化水至30g,混悬均匀,配制得到30ml 3%的胶原蛋白溶液;加入1.6×1.6cm模具后进行真空冷冻干燥,制得36片胶原膜;将胶原膜压片至厚度为0.5mm;在充氮真空烘箱于100℃进行干热交联6h即得所述天然双层重组类胶原蛋白可吸收生物膜;
其中,冷冻干燥工艺为:
(1)预冻第一阶段,在50min内,温度达1℃,并持续60min;预冻第二阶段,在50min内,温度达-45℃,并持续240min;
(2)对经预冻后的产物进行升华,真空度设为0.05mbar,在60min内,温度达-10℃,并持续300min;
(3)对经升华后的产物进行解析干燥,真空度设为0.1mbar,在40min内,温度达
25℃,并持续240min。
实施例16
本实施例提供了一种天然双层重组类胶原蛋白可吸收生物膜,其由以下步骤制得:
称量1.8g重组类胶原蛋白冻干粉(专利申请公布文本CN106554410A中实施例4所得重组人源胶原蛋白),加纯化水至30g,混悬均匀,配制得到30ml 6%的胶原蛋白溶液;加入1.6×1.6cm模具后进行真空冷冻干燥,制得36片胶原膜;将胶原膜压片至厚度为0.4mm;在充氮真空烘箱于140℃进行干热交联5h即得所述天然双层重组类胶原蛋白可吸收生物膜;
其中,冷冻干燥工艺为:
(1)预冻第一阶段,在40min内,温度达1℃,并持续50min;预冻第二阶段,在50min内,温度达-40℃,并持续300min;
(2)对经预冻后的产物进行升华,真空度设为0.09mbar,在50min内,温度达-20℃,并持续320min;
(3)对经升华后的产物进行解析干燥,真空度设为0.09mbar,在50min内,温度达30℃,并持续180min。
实施例17
本实施例提供了一种天然双层重组类胶原蛋白可吸收生物膜,其由以下步骤制得:
称量1.5g重组类胶原蛋白冻干粉(专利申请公布文本CN106554410A中实施例4所得重组人源胶原蛋白),加纯化水至30g,混悬均匀,配制得到30ml 5%的胶原蛋白溶液,加入1.6×1.6cm模具后进行真空冷冻干燥,制得36片胶原膜;将胶原膜压片至厚度为0.5mm;在充氮真空烘箱于200℃进行干热交联2.5h即得所述天然双层重组类胶原蛋白可吸收生物膜;
其中,冷冻干燥工艺为:
(1)预冻第一阶段,在30min内,温度达2℃,并持续60min;预冻第二阶段,在60min内,温度达-50℃,并持续240min;
(2)对经预冻后的产物进行升华,真空度设为0.07mbar,在60min内,温度达-5℃,并持续350min;
(3)对经升华后的产物进行解析干燥,真空度设为0.2mbar,在40min内,温度达35℃,并持续150min。
对比例1
本对比例提供了一种天然双层重组类胶原蛋白可吸收生物膜,其由以下步骤制得:
称量2.1g重组类胶原蛋白冻干粉(专利申请公布文本CN106554410A中实施例1所得重组人源胶原蛋白),加纯化水至30g,混悬均匀,配制得到30ml 7%的胶原蛋白溶液,加入1.6×1.6cm模具后进行真空冷冻干燥,制得36片胶原膜;将胶原膜压片至厚度为0.5mm;在鼓风干燥烘箱于240℃进行干热交联1.5h即得所述天然双层重组类胶原蛋白可吸收生物膜;
其中,冷冻干燥工艺为:
(1)预冻第一阶段,在30min内,温度达3℃,并持续60min;预冻第二阶段,在60min内,温度达-50℃,并持续240min;
(2)对经预冻后的产物进行升华,真空度设为0.07mbar,在60min内,温度达-5℃,并持续350min;
(3)对经升华后的产物进行解析干燥,真空度设为0.15mbar,在40min内,温度达35℃,并持续150min。
测试例
对实施例与对比例所得生物膜进行粘性、韧性、机械性能、生物相容性、促血管化性能的考察,以下所有检测均依据:YY/T 1794-2021《口腔胶原膜通用技术要求》。
分别在有氧、低氧、充氮气条件下经干热交联处理所得膜的外观如图6所示,性能考察结果见表1,可知在充氮气条件下交联处理的膜外观与最大延伸最佳。
实施例1所得生物膜具有良好的韧性,如图7所示;具有良好的粘性,如图8所示;不同胶原蛋白浓度的生物膜,其机械性能测试结果见表2-表4。
表1不同条件下生物膜的性能评价
表2生物膜抗拉伸强度
表3干态生物膜最大载荷
表4生物膜最大延伸
通过将实施例1所得生物膜在SD大鼠皮下包埋,于第三周取样纵切HE染色,切片染色如图9所示,可见该生物膜有大量细胞浸润,具有良好的生物相容性;实施例8所得生物膜的细胞相容性考察结果如图10所示,细胞在前三天持续增殖,表示该膜具有良好的细胞相容性,图10中6%胶原膜浸提液是指将胶原膜(制备过程中胶原蛋白溶液浓度为6%)置于培养基(H-DMEM+10%FBS)中浸提24h,用浸提液进行细胞接种96孔板;6%胶原原料是将实施例8采用的重组类胶原蛋白冻干粉加纯化水配置成6%的胶原溶液。实施例1所得生物膜促进血管化结果如图11所示,可见营养物质可顺利地穿透该膜,有利于伤口愈合,促进早期血管化,引导骨组织再生。
综上所述,仅是本发明的较佳实例而已,并非是对本发明作其他形式的限制,任何熟悉本专业的技术人员可能利用上述揭示的技术内容加以变更或改型为等同变化的等效实例。但是凡是未脱离本发明技术方案内容,依据本发明的技术实质对以上实施例所作的任何简单修改,等同变化与改型,仍属于本发明技术方案的保护范围。
Claims (15)
- 一种天然双层重组类胶原蛋白可吸收生物膜的制备方法,其包括以下步骤:(1)将胶原蛋白溶解到水中得到胶原蛋白溶液;(2)对上述胶原蛋白溶液进行冷冻干燥,得到胶原膜;(3)将上述胶原膜压制成薄膜;(4)对上述薄膜进行干热交联,得到所述天然双层重组类胶原蛋白可吸收生物膜。
- 根据权利要求1所述的制备方法,其中,步骤(1)中,所述胶原蛋白为CN106554410A所公开的重组人源胶原蛋白。
- 根据权利要求1所述的制备方法,其中,步骤(1)中,所述胶原蛋白溶液中胶原蛋白的质量浓度为0.5-15%。
- 根据权利要求1所述的制备方法,其中,步骤(1)中,所述胶原蛋白溶液中胶原蛋白的质量浓度为1-10%。
- 根据权利要求1所述的制备方法,其中,步骤(1)中,所述胶原蛋白溶液中胶原蛋白的质量浓度为1-7%。
- 根据权利要求1所述的制备方法,其中,步骤(2)中,所述冷冻干燥的工艺包括以下步骤:(1)预冻:分两个阶段进行,预冻第一阶段的工艺参数为在10-60min内,温度达0-4℃,并持续30-120min;预冻第二阶段的工艺参数为在10-60min内,温度达-60℃至-40℃,并持续120-480min;(2)升华:对经预冻后的产物进行升华,真空度设为0.05-0.5mbar,在10-60min内,温度达-40℃至-5℃,并持续120-480min;(3)解析干燥:对经升华后的产物进行解析干燥,真空度设为0.05-0.5mbar,在10-60min内,温度达0-40℃,并持续120-480min。
- 根据权利要求1所述的制备方法,其中,步骤(3)中,所述薄膜的厚度为0.1-1mm。
- 根据权利要求1所述的制备方法,其中,步骤(4)中,所述干热交联为:将所述薄膜置于真空度为-0.1MPa至-0.05MPa或氮气的环境中升温至100-250℃后保持1-6h。
- 根据权利要求8所述的制备方法,其中,所述干热交联中,升温的温度为100-230℃。
- 一种天然双层重组类胶原蛋白可吸收生物膜,其由权利要求1-9任一项所述的制备方法制得。
- 根据权利要求10所述的天然双层重组类胶原蛋白可吸收生物膜,其中,所述天然双层重组类胶原蛋白可吸收生物膜的一侧为致密结构,另一侧为疏松结构。
- 权利要求10或11所述的天然双层重组类胶原蛋白可吸收生物膜在制备口腔医用材料中的应用。
- 根据权利要求12所述的应用,其中,所述口腔医用材料为用于口腔修复或口腔外科手术的材料。
- 根据权利要求13所述的应用,其中,所述口腔修复包括牙齿种植。
- 根据权利要求12所述的应用,其中,所述天然双层重组类胶原蛋白可吸收生物膜在应用时,致密层朝外将非成骨细胞阻挡于骨缺损区以外,疏松层向内朝向骨缺损部位使成骨细胞顺利进入骨缺损区。
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202310018240.3A CN118304483A (zh) | 2023-01-06 | 2023-01-06 | 一种天然双层重组类胶原蛋白可吸收生物膜及其制备方法与应用 |
CN202310018240.3 | 2023-01-06 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2024146489A1 true WO2024146489A1 (zh) | 2024-07-11 |
Family
ID=91729859
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/CN2024/070015 WO2024146489A1 (zh) | 2023-01-06 | 2024-01-02 | 一种天然双层重组类胶原蛋白可吸收生物膜及其制备方法与应用 |
Country Status (2)
Country | Link |
---|---|
CN (1) | CN118304483A (zh) |
WO (1) | WO2024146489A1 (zh) |
Citations (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2003534102A (ja) * | 2000-05-26 | 2003-11-18 | コレティカ | 組織工学及び生体材料製造のためのコラーゲンベースによる支持体 |
CN104225689A (zh) * | 2013-06-08 | 2014-12-24 | 北京航空航天大学 | 一种鱼胶原骨诱导再生膜的制备方法 |
CN104922732A (zh) * | 2014-03-19 | 2015-09-23 | 北京天新福医疗器材有限公司 | 一种口腔生物膜制备方法 |
CN106554410A (zh) * | 2016-06-02 | 2017-04-05 | 陕西东大生化科技有限责任公司 | 一种重组人源胶原蛋白及其编码基因和制备方法 |
CN107050519A (zh) * | 2016-12-22 | 2017-08-18 | 天新福(北京)医疗器材股份有限公司 | 复层可吸收生物膜的制备方法 |
CN110743044A (zh) * | 2019-11-23 | 2020-02-04 | 北京银河巴马生物技术股份有限公司 | 一种口腔科骨引导再生胶原膜及其制备方法 |
CN112023119A (zh) * | 2020-08-28 | 2020-12-04 | 深圳齐康医疗器械有限公司 | 胶原基生物膜补片及其制备方法和应用 |
CN113018519A (zh) * | 2021-03-15 | 2021-06-25 | 武汉亚洲生物材料有限公司 | 矿化引导组织再生膜及其制备方法 |
CN113144294A (zh) * | 2021-02-20 | 2021-07-23 | 北京邦塞科技有限公司 | 三维多孔胶原支架的制备方法及三维多孔胶原支架、双层胶原支架及制备方法和应用 |
-
2023
- 2023-01-06 CN CN202310018240.3A patent/CN118304483A/zh active Pending
-
2024
- 2024-01-02 WO PCT/CN2024/070015 patent/WO2024146489A1/zh unknown
Patent Citations (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2003534102A (ja) * | 2000-05-26 | 2003-11-18 | コレティカ | 組織工学及び生体材料製造のためのコラーゲンベースによる支持体 |
CN104225689A (zh) * | 2013-06-08 | 2014-12-24 | 北京航空航天大学 | 一种鱼胶原骨诱导再生膜的制备方法 |
CN104922732A (zh) * | 2014-03-19 | 2015-09-23 | 北京天新福医疗器材有限公司 | 一种口腔生物膜制备方法 |
CN106554410A (zh) * | 2016-06-02 | 2017-04-05 | 陕西东大生化科技有限责任公司 | 一种重组人源胶原蛋白及其编码基因和制备方法 |
CN107050519A (zh) * | 2016-12-22 | 2017-08-18 | 天新福(北京)医疗器材股份有限公司 | 复层可吸收生物膜的制备方法 |
CN110743044A (zh) * | 2019-11-23 | 2020-02-04 | 北京银河巴马生物技术股份有限公司 | 一种口腔科骨引导再生胶原膜及其制备方法 |
CN112023119A (zh) * | 2020-08-28 | 2020-12-04 | 深圳齐康医疗器械有限公司 | 胶原基生物膜补片及其制备方法和应用 |
CN113144294A (zh) * | 2021-02-20 | 2021-07-23 | 北京邦塞科技有限公司 | 三维多孔胶原支架的制备方法及三维多孔胶原支架、双层胶原支架及制备方法和应用 |
CN113018519A (zh) * | 2021-03-15 | 2021-06-25 | 武汉亚洲生物材料有限公司 | 矿化引导组织再生膜及其制备方法 |
Also Published As
Publication number | Publication date |
---|---|
CN118304483A (zh) | 2024-07-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Tavelli et al. | Extracellular matrix‐based scaffolding technologies for periodontal and peri‐implant soft tissue regeneration | |
JP4615223B2 (ja) | コラーゲンバイオ繊維、ならびにその調製方法および使用 | |
Wang et al. | Regenerative porcine dermal collagen matrix developed by supercritical carbon dioxide extraction technology: Role in accelerated wound healing | |
CN108785657B (zh) | 组胺素1多肽在制备促进大面积皮肤缺损修复的复合材料中的应用 | |
US20050142161A1 (en) | Collagen matrix for soft tissue augmentation | |
Aurer et al. | Membranes for periodontal regeneration | |
JP2001508754A (ja) | 移植可能なものとしての合成タンパク質 | |
WO2008008266A2 (en) | Biohybrid elastomeric scaffolds and methods of use thereof | |
Tompkins et al. | Progress in burn treatment and the use of artificial skin | |
US20050107876A1 (en) | Dermal substitute consisting of amnion and biodegradable polymer, the preparation method and the use thereof | |
Ayala et al. | Evaluation of a bioengineered construct for tissue engineering applications | |
Omura et al. | A newly developed collagen/silicone bilayer membrane as a mucosal substitute: a preliminary report | |
KR101070411B1 (ko) | 고막재생용 인조 키토산 패치 | |
CN111840647A (zh) | 可吸收屏障膜及其制备方法 | |
WO2006021992A1 (ja) | コラーゲンスポンジの製造方法、人工皮膚の製造方法、人工皮膚及び細胞組織培養基材 | |
CN111700713A (zh) | 一种人工皮肤 | |
WO2024146489A1 (zh) | 一种天然双层重组类胶原蛋白可吸收生物膜及其制备方法与应用 | |
JP2006296896A (ja) | コラーゲン薄膜シート、その製造方法、それを用いた再建方法、および自己組織再生誘導型人工皮膚・粘膜 | |
WO1999060951A1 (en) | Compositions for regenerating tissue that has degenerated, and methods for using such compositions | |
Liu et al. | Anti-inflammatory effects of the immobilization of SEMA4D on titanium surfaces in an endothelial cell/macrophage indirect coculture model | |
KR101667390B1 (ko) | 치과 의료용 바이오셀룰로오스 차단막 및 그 제조 방법 | |
CN111228578A (zh) | 载药丝素蛋白骨修复螺钉及其制备方法 | |
CN109589455B (zh) | 一种热变性胶原蛋白或热变性真皮支架替代物及制备方法 | |
CN107982568A (zh) | 可降解生物辅料及其制备方法和应用 | |
Azab et al. | Biocompatibility evaluation of human and porcine acellular dermal matrix on human primary gingival fibroblasts: in vitro comparative study |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 24738422 Country of ref document: EP Kind code of ref document: A1 |